Jefferies Cuts Price Target on Red Hat (RHT) to $76 Following 3Q Report

Deutsche Bank Cuts Price Target on Red Hat (RHT) to $90 Following 3Q Report

Deutsche Bank maintained a Buy rating on Red Hat (NYSE: RHT), and cut the price target to $90.00 (from $95.00), following the company's 3Q earnings report.

Analyst... More

JMP Securities Cuts Price Target on Red Hat (RHT) Following Mixed 3Q

JMP Securities maintained a Market Outperform rating on Red Hat (NYSE: RHT), and cut the price target to $93.00 (from $97.00), following the company's 3Q earnings... More

Needham & Company Cuts Price Target on Red Hat (RHT) Following 3Q Report

Needham & Company maintained a Buy rating on Red Hat (NYSE: RHT), and cut the price target to $89.00 (from $98.00), following the company's 3Q earnings report. For FY17, RHT lowered revenue by -24m and cash flow from operations by -32m at the midpoint; opmgn remains 23% and EPS was raised by $0.03 for... More

Stifel Downgrades Red Hat (RHT) to Hold

Stifel downgraded Red Hat (NYSE: RHT) from Buy to Hold with a price target of $70.00 (from $87.00).

For an analyst ratings summary and ratings history on Red Hat click here. For more ratings news on Red Hat click here.

Shares of Red Hat closed at $79.79 yesterday.

UPDATE: BMO Capital Downgrades Red Hat (RHT) to Market Perform

(Updated - December 22, 2016 8:44 AM EST)

BMO Capital downgraded Red Hat (NYSE: RHT) from Outperform to Market Perform with a price target of $75.00 (from $89.00).

Analyst Keith Bachman commented, "We are downgrading RHT from an Outperform to a Market Perform rating. We are lowering... More

Red Hat (RHT): Cutting PT to $80 From $88 - Mizuho

Mizuho Securities analyst, Abhey Lamba, cut his price target but reiterated his Buy rating on shares of Red Hat (NYSE: RHT) after the company reported third quarter results that came in below expectations.

The company called out FX and slipped deals as... More

After-Hours Stock Movers 12/21: (XOMA) (MU) Higher; (OVAS) (RHT) (MLHR) Lower (more...)

Today's After-Hours Movers

OvaScience (NASDAQ: OVAS) 32.7% LOWER; The Company will continue to make AUGMENTSM available to patients at partner clinics in Canada and Japan and maintain its current commercial footprint. However, the Company will slow its commercial expansion, reassess its ongoing and planned clinical studies of AUGMENT, and undertake a corporate restructuring. These changes will enable the Company to extend its cash position into the first quarter of 2019 and increase its focus on the development of OvaPrimeSM and OvaTureSM. In connection with this shift in strategy, President and... More

Red Hat (RHT) CFO Frank Calderoni to Step Down

Red Hat (NYSE: RHT) announced Frank Calderoni notified Red Hat of his decision to step down as Executive Vice President, Operations and Chief Financial Officer of Red Hat, effective in late January 2017, to enable him to accept a chief executive officer position at another... More

Red Hat (RHT) Tops Q3 EPS by 3c; CFO to Resign

Red Hat (NYSE: RHT) reported Q3 EPS of $0.61, $0.03 better than the analyst estimate of $0.58. Revenue for the quarter came in at $615 million, p 18% year-over-year or 17% in constant currency, versus the consensus estimate of $618.02 million.

Frank Calderoni notified Red Hat of his decision to... More

Red Hat (RHT) December weekly 79.50 straddle priced for movement of 5.4% into Q3

Red Hat (NYSE: RHT) December weekly 79.50 straddle priced for movement of 5.4% into Q3

UBS Reiterates Buy on Red Hat (RHT) as Survey Shows High Interest Levels

UBS reiterated a Buy rating and $90.00 price target on Red Hat (NYSE: RHT) following a... More